Genmab A/S Dkk (GNMSF) 95.3300 $GNMSF Major Shareholder

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 95.3300 $GNMSF

Major Shareholder Announcement
GlobeNewswire - Thu Oct 08, 11:01AM CDT
Company Announcement
GEN: 5.92 (+0.11)

Genmab Reaches $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Mon Oct 05, 8:51AM CDT
-- Genmab to receive $3 million milestone payment in DuoBody(r) collaboration with Janssen
GEN: 5.92 (+0.11)

CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma
GlobeNewswire - Fri Sep 25, 4:14AM CDT
Company Announcement
GEN: 5.92 (+0.11)

U.S. FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Sat Sep 19, 8:49AM CDT
Company Announcement
GEN: 5.92 (+0.11)

Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma
GlobeNewswire - Wed Sep 09, 6:38AM CDT
-- MAA submitted to EMA by Janssen for daratumumab in multiple myeloma
GEN: 5.92 (+0.11)

Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 10.92 (+0.32), PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), STML: 9.68 (unch)

U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
GlobeNewswire - Fri Sep 04, 1:25PM CDT
-- U.S. FDA grants Priority Review to daratumumab
GEN: 5.92 (+0.11)

Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
GlobeNewswire - Fri Aug 14, 5:37AM CDT
-- Two commercial DuoBody
NVO: 54.61 (-0.12), GEN: 5.92 (+0.11)

Genmab Announces Financial Results for the First Half of 2015
GlobeNewswire - Wed Aug 12, 12:59AM CDT
Interim Report First Half 2015

Bladder Cancer Pipeline Review, H1 2015 - 80 Companies & 119 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shdv3w/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Advaxis, Inc. - Alligator Bioscience AB - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - AndroScience Corporation - APIM Therapeutics AS - Arno Therapeutics, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AuraSense Therapeutics, LLC - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Bavarian Nordic A/S - Bayer AG - BioCancell Ltd - Bioncotech Therapeutics S.L. - Biotest AG - cCAM Biotherapeutics Ltd. - Celgene Corporation - Cold Genesys, Inc. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DormaTarg, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - Esperance Pharmaceuticals, Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - GlaxoSmithKline Plc - Heat Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/sh...der_cancer
HTBX: 4.25 (+0.03), ADXS: 11.07 (+0.83), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), CELGZ: 1.74 (+0.04)

Pemphigus Vulgaris Pipeline Review, H1 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Jul 28, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ms9fp4/pemphigus) has announced the addition of the "Pemphigus Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biogen, Inc. - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Novartis AG Drug Profiles - DP-C006 - HL-161 - ofatumumab - rituximab - T-Cell Therapy for Pemphigus Vulgaris - VAY-736 - veltuzumab For more information visit http://www.researchandmarkets.com/research/ms9fp4/pemphigus
IMMU: 2.17 (+0.12), NVS: 91.90 (-0.71)

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Wed Jul 22, 7:27AM CDT
Company Announcement
GEN: 5.92 (+0.11)

Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 102.69 (+1.97), ARQL: 2.04 (+0.05), GALE: 1.74 (+0.01), EXEL: 5.99 (+0.14), XLRN: 24.08 (-0.18), INCY: 105.00 (+1.56), IMGN: 10.91 (+0.25), GSK: 40.22 (+0.06), ONTY: 2.88 (+0.08), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), AVEO: 1.27 (+0.05), PBYI: 79.41 (+3.89), KPTI: 11.75 (+0.04), NVS: 91.90 (-0.71)

Major Shareholder Announcement for Genmab A/S
GlobeNewswire - Fri Jul 10, 10:54AM CDT
Genmab A/S (OMX:GEN) announces under reference to Section 29 of the Danish Securities Trading Act that ATP has informed us that ATP and AES as of July 10, 2015 have reduced their ownership of the share capital and voting rights in Genmab A/S to below the 5% threshold.
GEN: 5.92 (+0.11)

Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
GlobeNewswire - Thu Jul 09, 12:53PM CDT
-- Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc.
GEN: 5.92 (+0.11)

Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 12.80 (+0.53), GSK: 40.22 (+0.06), XNPT: 4.19 (+0.26), SYN: 2.41 (+0.03), OPXA: 3.20 (-0.08), FWP: 27.74 (+0.87), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)

Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.17 (+0.12), PFE: 33.24 (+0.15), INCY: 105.00 (+1.56), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), AMGN: 149.59 (-0.31)

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Tue Jul 07, 6:40AM CDT
Company Announcement
GEN: 5.92 (+0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 17

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 0

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 0

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 39

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 51

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

GrandCare Health Services Enhances Revenue with Smart Solutions

Updated Category News Views 120

GrandCare Health Services Takes a New Approach to Revenue Management In a strategic move to enhance its financial efficiency, GrandCare Health Services has recently partnered with Homecare Homebase (HCHB), a leading provider of cloud-based technological solutions designed for home health agencies. This collaboration specifically focuses on optimizing revenue cycle...

Continue Reading
Westland Insurance Expands its Ontario Footprint with Acquisition

Updated Category News Views 216

Westland Insurance Expands its Ontario Presence Westland Insurance, a prominent name in Canada’s insurance market, has made strides in enhancing its reach with the acquisition of Paul Ayotte Insurance Brokers Ltd. This strategic move aims to solidify Westland’s footprint in Ontario, allowing for improved service delivery to local clients. This acquisition not only...

Continue Reading
First Industrial Realty Trust Set for Q3 Results Conference Call

Updated Category News Views 50

First Industrial Realty Trust, Inc. (NYSE: FR) faced a pivotal moment back in late 2024, gearing up to unveil its third-quarter numbers. The desks were buzzing as traders anticipated this call—a regular event but always loaded with potential surprises. Q3 Results Anticipation: Supply Chain Stakes or Investor Optimism? On that Thursday morning, scheduled for 10:00 a.m....

Continue Reading
Fannie Mae Panel Predicts Slowdown in Future Home Prices

Updated Category News Views 217

Fannie Mae's Expert Insights on Home Price Trends A recent survey conducted by Fannie Mae proves insightful for those watching the housing market, as it sheds light on anticipated changes in home prices in the coming years. The report indicates that after an increase of 5.3% in 2024, experts expect a more moderate growth of approximately 2.4% for 2025 and 2.1% for 2026....

Continue Reading
PenKid Biomarker Revolutionizes Kidney Therapy Decisions

Updated Category News Views 31

The Emergence of PenKid in Critical Care You ever get the feeling that the old ways just aren’t cutting it anymore? That’s where this penKid news rolls in like a breath of fresh air. In the world of ICU management, especially with kidney replacement therapy (KRT), this little biomarker is flipping the script on traditional biomarkers. Imagine 1,436 critically ill...

Continue Reading